Transcription factor MEF2D regulates aberrant expression of ACSL3 and enhances sorafenib resistance by inhibiting ferroptosis in HCC
This study demonstrated for the first time that MEF2D regulated ACSL3 expression and mediated sorafenib resistance by inhibiting ferroptosis in HCC, providing a potential therapeutic target for improving HCC outcomes.
Authors
- X Wang (ORCID: https://orcid.org/0000-0002-6920-8104)
- Leina Ma (ORCID: https://orcid.org/0000-0003-3964-632X)
- Yuanyuan Shi (ORCID: https://orcid.org/0000-0003-1593-1767)
- Chao Wu (ORCID: https://orcid.org/0000-0003-0260-2868)
- Xue Li (ORCID: https://orcid.org/0000-0003-2452-6106)
- Wenshuo Fang
- Shimin Chen (ORCID: https://orcid.org/0000-0002-9025-093X)
- Qian Lin (ORCID: https://orcid.org/0000-0002-2019-0986)
- Peng Sun (ORCID: https://orcid.org/0000-0002-1931-3694)
- Yuanjing Wang (ORCID: https://orcid.org/0000-0003-1972-4634)
Institutions
- Qingdao University (CN)
- Affiliated Hospital of Qingdao University (CN)
- Weifang Maternity and Child Care Hospital (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2024-12-18
- DOI
- https://doi.org/10.3389/fphar.2024.1464852
- Citations
- 10
- Primary Topic
- Ferroptosis and cancer prognosis
- Type
- article
- Field-Weighted Citation Impact
- 4.19
Funders
- National Natural Science Foundation of China
- Natural Science Foundation of Shandong Province